AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04960137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: button plates fixation system
Description: The button plates fixation system consists of fixing plate, prefabricated mix, button and fuse. In the process of use, the fuse plays the role of guiding the fixed plate through, pulling the button and shortening the distance between the button and the fixed plate. The prefabricated mix is pre-worn between the button and the fixed plate, and the lead pulls the distance between the fixed plate and the button after tightening and fixing. Prefabricated mix, make mix tight and knot. Finish the preliminary work of fixing.
Study NCT04960137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-absorbable Suture Anchor
Description: A conventional device used in surgery for shoulder dislocation.
Study NCT02151552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endotoxin (E. coli O:113, Reference Endotoxin)
Description: The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
Study NCT02646631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants assigned to this treatment will receive the usual care as determined by their physician
Study NCT02646631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants assigned to this treatment will receive the usual care as determined by their physician
Study NCT02646631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Management of Risks in Epilepsy (MORE)
Description: MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
Study NCT02646631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Management of Risks in Epilepsy (MORE)
Description: MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
Study NCT02646631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-based motivational interviewing (MORE+MI)
Description: Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
Study NCT02646631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Materials
Description: Printed educational materials on the management of epilepsy
Study NCT02646631 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Materials
Description: Printed educational materials on the management of epilepsy
Study NCT02961959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Arthrodesis of SI-joints, Physiotherapy
Study NCT02961959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgery
Description: Physiotherapy
Study NCT02151552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F](+/-)NOS
Description: 7 mCi of \[18F\](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
Study NCT04279873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological diagnostics on pulmonary secretion
Description: Culture, 16s, 18s, next generation sequencing
Study NCT02218645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WE 941 OD tablets
Study NCT02218645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brotizolam
Study NCT00746278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy using bipolar
Description: Laparoscopic ovarian cystectomy using bipolar
Study NCT00746278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cystectomy using ultrasonic scalpel
Description: Laparoscopic ovarian cystectomy using ultrasonic scalpel
Study NCT00746278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian cystectomy using suture
Description: Laparoscopic ovarian cystectomy using suture
Study NCT00130169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7974
Description: Maximum Tolerated Dose defined as 0.35 mg/m\^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
Study NCT01367834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatotropin
Description: Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
Study NCT00240461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: COLD-fX natural health product
Description: 200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
Study NCT00240461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: COLD-fX
Description: 400 mg COLD-fX natural health product 2 times daily for 6 months
Study NCT00240461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: crystalline substance 200 mg twice daily for 6 months
Study NCT05114408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 week trimodal prehabilitation course
Description: trimodal prehabilitation in mixed: stationary and at-home structure
Study NCT03686904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzalkonium Gel
Description: antibiofilm solution (BlastX) topical wound gel
Study NCT02190162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tantum Verde® mouthwash
Study NCT02190162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Mouthwash with placebo solution
Study NCT03712462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Weight Loss Therapy for BED
Description: ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
Study NCT03712462 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavior Therapy
Description: SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
Study NCT02594566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyMVectin
Description: CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
Study NCT01307189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium diskus inhalation powder, 18ug, once daily
Study NCT01307189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo diskus inhalation powder, once daily
Study NCT02001662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group, block no. 1 - Ropivacain
Description: Intervention group: 1. block ropivacaine - 2. block saline
Study NCT02001662 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group: 1. block - saline
Description: Control group: 1. block saline - 2. block ropivacaine
Study NCT03148912 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic algorithm
Description: The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
Study NCT00379821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Description: Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
Study NCT00379821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
Study NCT00379821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
Study NCT00379821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
Study NCT03686904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care topical gel
Description: standard of care topical gel (hydrocolloid topical gel)
Study NCT03686904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care topical gel
Description: standard of care topical gel (hydrocolloid topical gel)
Study NCT03686904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)
Study NCT03686904 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Debridement
Description: Removing dead tissue from infected wound (in clinic)
Study NCT03686904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzalkonium irrigation
Description: washing and lavaging in clinic with benzalkonium irrigation
Study NCT03686904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline Irrigation (SOC Irrigation)
Description: Normal Saline Irrigation (SOC Irrigation)
Study NCT03686904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Irrigation (SOC Irrigation)
Description: Normal Saline Irrigation (SOC Irrigation)
Study NCT00870181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADV-TK/GCV
Description: gene therapy
Study NCT00870181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study NCT00870181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Study NCT03355846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella
Description: after meals twice a day for 15 days
Study NCT03355846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proctocella
Description: after hygiene treatment for 4 weeks;
Study NCT03355846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonil® cps
Description: after meals twice a day for 15 days
Study NCT03355846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonil® Cream
Description: treatment for 4 weeks;~.
Study NCT03855774 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Polymorphisms
Description: Classification of sleep disorders using 22 genetic polymorphisms
Study NCT03355846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectalgan Mousse
Description: for 4 weeks
Study NCT04212598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients who completed concurrent chemoradiotherapy standard dose would received the Sintilimab as a consolidate therapy for one year.
Study NCT04917484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177-DOTA-Octreotide
Description: Lu-177-DOTATOC in standard doses or individualized doses.
Study NCT04917484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lu-177-DOTA-Octreotide
Description: Lu-177-DOTATOC in standard doses or individualized doses.
Study NCT00724672 — intervention group
Intervention type: DRUG
Intervention: etanercept
Description: etanercept 50 mg subcutaneously once weekly
Study NCT00724672 — intervention group
Intervention type: DRUG
Intervention: infliximab
Description: infliximab 3 mg/kg IV at Weeks 0, 2, and 6
Study NCT00724672 — intervention group
Intervention type: DRUG
Intervention: adalimumab
Description: adalimumab 40 mg subcutaneously biweekly
Study NCT00672919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
Study NCT00970112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: Open flap debridement - access flap + scaling and root planning
Study NCT00970112 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open Flap Debridement
Description: Open flap debridement - access flap + scaling and root planning
Study NCT03257124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291 160mg per oral daily (1 cycle of 28 days)
Study NCT01176058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anidulafungin/Fluconazole
Description: Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
Study NCT04203836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 152020 Tablet
Description: film-coated tablet
Study NCT01217463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study NCT01217463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trafermin 0.01% spray
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study NCT03337334 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency
Study NCT03817619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier crushed tablet
Description: Single-dose crushed ELB/GZR in a fasted state.
Study NCT03125512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Night Shift positional device
Description: Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
Study NCT03125512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Automated adjusting continuous positive airway pressure
Study NCT02327676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: emtricitabine were given to each patients for 48 weeks
Study NCT02713724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
Study NCT02713724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: limited physical exercise
Description: The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
Study NCT02686918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Practice Nurse consultation
Study NCT02041481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK inhibitor MEK162
Description: Given PO
Study NCT02041481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT03904602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edema Wear fuzzy wale compression garment
Description: net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
Study NCT02853825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Skill Enhancement
Description: Receive relationship classes with access to parenting, employment services, and financial services.
Study NCT02041481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT05170217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: Inhaled cannabis containing 10mg THC
Study NCT05170217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 10mg CBD
Study NCT02041481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02041481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02041481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT03641378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
Study NCT02882594 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observing patient behaviors for anesthesia induction compliance
Description: Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
Study NCT01314001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Study NCT01314001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch
Study NCT05170217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 20mg CBD
Study NCT05170217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Inhaled cannabis containing 30mg CBD
Study NCT01314001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine
Description: Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
Study NCT03544021 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
Study NCT00182039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release (CR)
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
Study NCT00182039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
Study NCT03573323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC